Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gest...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Tim R. Cressey, Luc Decker, Woottichai Khamduang, Linda Harrison, Camlin Tierney, John A. Shepherd, Athena P. Kourtis, Marc Bulterys, George K. Siberry, Gonzague Jourdain
Format: Journal
Published: 2019
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068428450&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/65731
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Description
Summary:© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

Similar Items